Applicability of the Fagerström Test for Nicotine Dependence in smokers with schizophrenia

Addictive Behaviors

Volumn 30, Issue 1, 2005, Pages 49-59

  Steinberg, Marc L ^a   Williams, Jill M ^a   Steinberg, Howard R ^b   Krejci, Jonathan A ^a   Ziedonis, Douglas M ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Assessment; Cigarette; Nicotine dependence; Reliability; Schizophrenia; Tobacco

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DISEASE SEVERITY; DRUG DEPENDENCE; FEMALE; HUMAN; MALE; POPULATION; RELIABILITY; SCHIZOPHRENIA; SMOKING; TOBACCO DEPENDENCE;

ADULT; BREATH TESTS; CARBON MONOXIDE; DIAGNOSIS, DUAL (PSYCHIATRY); FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIC PSYCHOLOGY; TOBACCO USE DISORDER;

EID: 9244222720     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2004.04.012     Document Type: Article

References (35)

1. Addington J., el Guebaly N., Campbell W., Hodgins D.C., Addington D. Smoking cessation treatment for patients with schizophrenia. American Journal of Psychiatry. 155:1998;974-976
2. Breslau N., Johnson E.O. Predicting smoking cessation and major depression in nicotine-dependent smokers. American Journal of Public Health. 90(7):2000;1122-1127
3. Caskey N.H., Olmstead R.E., Jarvik M.E., Madsen D.C., Griffith T., Terrace S., Wirshing W.C. Smoking topography in patients with schizophrenia vs. normal smokers. Poster presented at the 9th Annual Meeting of the Society for Research on Nicotine and Tobacco New Orleans, LA.:2003
4. Cattell R.B. The scientific use of factor analysis. 1978;Plenum, New York
5. Centers for Disease Control (2001). Tobacco information and prevention source. http://www.cdc.gov/tobacco/research_data/adults_prev/tab_3.htm
6. Coovert M.D., McNelis K. Determining the number of common factors in factor analysis: A review and program. Educational and Psychological Measurement. 48:1988;687-692
7. de Leon J., Abraham G., Nair C., Verghese C., McGrory A., McCann E. Nicotine addiction in chronic schizophrenic inpatients. Biological Psychiatry. 37:1995;593-683
8. de Leon J., Diaz F.J., Rogers T., Browne D., Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophrenia Research. 56:2002;47-54
9. de Leon J., Tracy J., McCann E., McGrory A., Diaz F.J. Schizophrenia and tobacco smoking: A replication study in another U.S. psychiatric hospital. Schizophrenia Research. 56:2002;55-65
10. Everitt B.S. Multivariate analysis: The need for data, and other problems. British Journal of Psychiatry. 126:1975;237-240
11. First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (2001). Structured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition. (SCID-I/P) New York: Biometrics Research, New York State Psychiatric Institute.
12. George T.P., Vessicchio J.C., Termine A., Bregartner T.A., Feingold A., Rounsaville B.J., Kosten T.R. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological Psychiatry. 52(1):2002;53-61
13. George T.P., Ziedonis D.M., Feingold A., Pepper W.T., Satterburg C.A., Winkel J., Rounsaville B.J., Kosten T.R. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry. 157:2000;1835-1842
14. GlaxoSmithKline Consumer Healthcare (2003). Choosing the right strength. http://www.commitlozenge.quit.com/how/default.aspx?id=25
15. Gorsuch R.L. Factor analysis. 2nd ed.:1983;McGraw Hill, New York
16. Haddock C.K., Lando H., Klesges R.C., Talcott W., Renaud E.A. A study of the psychometric and predictive properties of the Fagerström Test for Nicotine Dependence in a population of young smokers. Nicotine & Tobacco Research. 1:1999;59-66
17. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addictions. 86:1991;1119-1127
18. Jeste D.V., Gladsjo J.A., Lindamer L.A., Lacro J.P. Medical comorbidity in schizophrenia. Schizophrenia Bulletin. 22(3):1996;413-430
19. Kelly C., McCreadie R.G. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. American Journal of Psychiatry. 156:1999;751-1757
20. MacCallum R.C., Widaman K.F., Zhang S., Hong S. Sample size in factor analysis. Psychological Methods. 4(1):1999;84-99
21. National Institute of Drug Abuse (April 1999). Consensus statement on evaluation of outcomes for pharmacotherapy for substance abuse/dependence. Washington, DC.
22. Nunnally J.C. Psychometric theory. 2nd ed.:1978;McGraw-Hill, New York
23. Olincy A., Young D.A., Freedman R. Increased levels of nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biological Psychiatry. 42:1997;1-5
24. Payne T.J., Smith P.O., McCracken L.M., McSherry W.C., Antony M.M. Assessing nicotine dependence: A comparison of the Fagerström Tolerance Questionnaire (FTQ) with the Fagerström Test for Nicotine Dependence (FTND) in a clinical sample. Addictive Behaviors. 19(3):1994;307-317
25. Pomerleau C.S., Carton S.M., Lutzke M.L., Flessland K.A., Pomerleau O.F. Reliability of the Fagerström Tolerance Questionnaire and the Fagerström Test for Nicotine Dependence. Addictive Behaviors. 19(1):1994;33-39
26. Prokhorov A.V., Pallonen U.E., Fava J.L., Ding L., Niaura R. Measuring nicotine dependence among high-risk adolescent smokers. Addictive Behaviors. 21(1):1996;117-127
27. Radzius A., Gallo J.J., Epstein D.H., Gorelick D.A., Cadet J.L., Uhl G.E., Moolchan E.T. A factor analysis of the Fagerström Test for Nicotine Dependence (FTND). Nicotine & Tobacco Research. 5(2):2003;255-260
28. Rummel R.J. Applied factor analysis. 1970;Northwestern Univ. Press, Evanston
29. Shiffman S., Dresler C.M., Hajek P., Gilburt S.J.A., Targett D.A., Strahs K.R. Efficacy of a nicotine lozenge for smoking cessation. Archives of Internal Medicine. 162:2002;1267-1276
30. Steinberg, M. L., Ziedonis, D. M., Krejci, J. A., Brandon, T. H. (2004). Motivational interviewing with personalized feedback: A brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. Journal of Consulting and Clinical Psychology.
31. Tidey J.W., O'Neil S.C., Higgins S.T. Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Experimental and Clinical Psychopharmacology. 10(3):2002;241-247
32. Weiner E., Ball M.P., Summerfelt A., Gold J., Buchanan R.W. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. American Journal of Psychiatry. 158(4):2001;635-637
33. Yang Y.K., McEvoy J.P., Wilson W.H., Levin E.D., Rose J.E. Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia. Schizophrenia Research. 60:2003;9-12
34. Ziedonis D.M., George T.P. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophrenia Bulletin. 23(2):1997;247-254
35. Zwick W.R., Velicer W.F. Comparison of five rules for determining the number of components to retain. Psychological Bulletin. 99:1986;432-442